Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology

• Published in: Clinical ophthalmology (Auckland, N.Z.) Vol. 1; no. 4; pp. 393 - 402
• Main Authors: Trujillo, Cleber A, Nery, Arthur A, Alves, Janaína M, Martins, Antonio H, Ulrich, Henning
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.12.2007; Dove Medical Press
• Subjects: Ligands; Macular degeneration; Review; Vascular endothelial growth factor; pegaptanib; anti-VEGF aptamer; age-related macular degeneration
• ISSN: 1177-5467; 1177-5483

Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF(165)). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF(165) and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects.